Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging standardization in pharmacoeconomics

C D Mullins1, S Ogilvie

  • 1University of Maryland School of Pharmacy, Baltimore 21201-1563, USA.

Clinical Therapeutics
|January 23, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.

BJOG : an international journal of obstetrics and gynaecology·2022
Same author

What works when: mapping patient and stakeholder engagement methods along the ten-step continuum framework.

Journal of comparative effectiveness research·2021
Same author

Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing.

Alzheimer disease and associated disorders·2019
Same author

Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids.

Lupus·2017
Same author

Endpoints in Pain: the Suitability for Health Economic Evaluation of Endpoint Designs in Chronic Pain Studies.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.

PharmacoEconomics·2014
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
Same journal

Diversity: A Medical Research Imperative.

Clinical therapeutics·2026
Same journal

LOARGYS (pegzilarginase-nbln).

Clinical therapeutics·2026
See all related articles

Pharmacoeconomic guidelines show emerging standardization in transparent methods and bias reduction. However, significant differences persist in assessment types, data sources, and analysis, impacting consistency versus validity.

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Health Policy

Background:

  • Pharmacoeconomic evaluations are crucial for healthcare decision-making.
  • International guidelines aim to standardize these assessments.
  • Varying guidelines can lead to inconsistencies in economic evaluations.

Purpose of the Study:

  • To identify areas of emerging standardization in pharmacoeconomic guidelines.
  • To compare and contrast key elements across international pharmacoeconomic guidelines.
  • To understand the factors influencing the evolution of economic guidelines.

Main Methods:

  • Systematic review of pharmacoeconomic guidelines from six countries (UK, Spain, Italy, Australia, Canada, US).
  • Analysis of published literature, journal guidelines, and task force recommendations.

Related Experiment Videos

  • Comparative analysis of common principles and divergent topics across guidelines.

    • Main Results:

    • Consensus exists on transparent methods, bias minimization, and justification of assumptions.
    • Key differences identified in assessment type, perspective, comparators, data sources, analysis, outcomes, modeling, time horizon, discounting, disclosure, and generalizability.
    • Emerging standardization focuses on methodological transparency.

    Conclusions:

    • Pharmacoeconomic guidelines are evolving with a tension between increasing consistency and validity.
    • Achieving a balance between consistency and validity is essential for robust economic assessments.
    • Further harmonization is needed in specific areas to improve comparability of evaluations.